Advertisement

Therapeutic Application of Cell Microencapsulation in Cancer

  • Brian Salmons
  • Walter H. Gunzburg
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 670)

Abstract

Although cell encapsulation technologies were originally developed for the treatment of acquired and genetic diseases such as diabetes, they can also be applied to the treatment of a variety of solid tumours. There are a number of strategies aimed at treating tumours with encapsulated cells and most of these are reviewed in this chapter. Many of these strategies have shown promise in preclinical studies and clinical trials.

Keywords

Suicide Gene Cytosine Deaminase Tumour Necrosis Factor Related Apoptosis Induce Ligand Encapsulate Cell Cellulose Sulphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Orive G, Hernández RM, Gascón AR et al. Cell encapsulation: promise and progress. Nat Med 2003; 9:104–107.CrossRefPubMedGoogle Scholar
  2. 2.
    Chang TMS. Therapeutic applications of polymeric artificial cells. Nat Rev Drug Discovery 2005; 4:221–235.CrossRefGoogle Scholar
  3. 3.
    Wilson JT, Chaikof EL. Challenges and emerging technologies in the immunoisolation of cells and tissues. Adv Drug Deliv Rev 2008; 60:124–145.CrossRefPubMedGoogle Scholar
  4. 4.
    Hauser O, Prieschl-Grassauer E, Salmons B. Encapsulated, genetically modified cells producing in vivo therapeutics. Curr Opin Mol Ther 2004; 6:412–420.PubMedGoogle Scholar
  5. 5.
    Cirone P, Potter M, Hirte H et al. Immuno-isolation in cancer gene therapy. Curr Gene Ther 2006; 6:181–191.CrossRefPubMedGoogle Scholar
  6. 6.
    Hamilton MJ, Huang QX, Li CL et al. The development and characterization of an HEK293-derived cell line for use in an intratumoral cytokine delivery system. Cell Transplant 2006; 15:343–350.CrossRefPubMedGoogle Scholar
  7. 7. F
    olkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–1186.CrossRefGoogle Scholar
  8. 8.
    O’Reilly MS, Holmgren L, Shing Y et al. Angiostatin: a circulating endothelial cell inhibitor that suppresses angiogenesis and tumor growth. Cold Spring Harb Symp Quant Biol 1994; 59:471–482.PubMedGoogle Scholar
  9. 9.
    O’Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277–285.CrossRefPubMedGoogle Scholar
  10. 10.
    Cao R, Wu HL, Veitonmäki N et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1996; 96:5728–5733.CrossRefGoogle Scholar
  11. 11.
    Eder JP Jr, Supko JG, Clark JW et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002; 20:3772–3784.CrossRefPubMedGoogle Scholar
  12. 12.
    Indraccolo S. Undermining tumor angiogenesis by gene therapy: an emerging field. Curr Gene Ther 2004; 4:297–308.PubMedGoogle Scholar
  13. 13.
    Read TA, Sorensen DR, Mahesparan R et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 2001; 19:29–34.CrossRefPubMedGoogle Scholar
  14. 14.
    Read TA, Farhadi M, Bjerkvig R et al. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells. Cancer Res 2001; 61:6830–6837.PubMedGoogle Scholar
  15. 15.
    Bjerkvig R, Read TA, Vajkoczy P et al. Cell therapy using encapsulated cells producing endostatin. Acta Neurochir Suppl 2003; 88:137–141.PubMedGoogle Scholar
  16. 16.
    Joki T, Machluf M, Atala A et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 2001; 19:35–39.CrossRefPubMedGoogle Scholar
  17. 17.
    Teng H, Zhang Y, Wang W et al. Inhibition of tumor growth in mice by endostatin derived from abdominal transplanted encapsulated cells. Acta Biochim Biophys Sin (Shanghai) 2007; 39:278–284.CrossRefGoogle Scholar
  18. 18.
    Zhang Y, Wang W, Xie Y et al. In vivo culture of encapsulated endostatin-secreting Chinese hamster ovary cells for systemic tumor inhibition. Hum Gene Ther 2007; 18:474–481.CrossRefPubMedGoogle Scholar
  19. 19.
    Schuch G, Oliveira-Ferrer L, Loges S et al. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo. Leukemia 2005; 19:1312–1317.CrossRefPubMedGoogle Scholar
  20. 20.
    Cirone P, Bourgeois JM, Chang PL. Antiangiogenic cancer therapy with microencapsulated cells. Hum Gene Ther 2003; 14:1065–1077.CrossRefPubMedGoogle Scholar
  21. 21.
    Li AA, Shen F, Zhang T et al. Enhancement of myoblast microencapsulation for gene therapy. J Biomed Mater Res B Appl Biomater 2006; 77:296–306.PubMedGoogle Scholar
  22. 22.
    Bartsch G Jr, Eggert K, Soker S et al. Combined antiangiogenic therapy is superior to single inhibitors in a model of renal cell carcinoma. J Urol 2008; 179:326–332.CrossRefPubMedGoogle Scholar
  23. 23.
    Hao S, Su L, Guo X et al. A novel approach to tumor suppression using microencapsulated engineered J558/TNF-alpha cells. Exp Oncol 2005; 27:56–60.PubMedGoogle Scholar
  24. 24.
    Moran DM, Koniaris LG, Jablonski EM et al. Microencapsulation of engineered cells to deliver sustained high circulating levels of interleukin-6 to study hepatocellular carcinoma progression. Cell Transplant 2006; 15:785–798.CrossRefPubMedGoogle Scholar
  25. 25.
    Pelegrin M, Marin M, Noël D et al. Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells. Gene Ther 1998; 5:828–834.CrossRefPubMedGoogle Scholar
  26. 26.
    Dautzenberg H, Schuldt U, Grasnick G et al. Development of cellulose sulfate-based polyelectrolyte complex microcapsules for medical applications. Ann N Y Acad Sci 1999; 875:46–63.CrossRefPubMedGoogle Scholar
  27. 27.
    Pelegrin M, Marin M, Oates A et al. Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies. Hum Gene Ther 2000; 11:1407–1415.CrossRefPubMedGoogle Scholar
  28. 28.
    Shi M, Hao S, Quereshi M. Significant tumor regression induced by microencapsulation of recombinant tumor cells secreting fusion protein. Cancer Biother Radiopharm 2005; 20:260–266.CrossRefPubMedGoogle Scholar
  29. 29.
    Xiang J, Moyana T, Qi Y. Genetic engineering of a recombinant fusion possessing anti-tumor F(ab’)2 and tumor necrosis factor. J Biotechnol 1997; 53:3–12.CrossRefPubMedGoogle Scholar
  30. 30.
    Kuijlen JM, de Haan BJ, Helfrich W et al. The efficacy of alginate encapsulated CHO-K1 single chain-TRAIL producer cells in the treatment of brain tumors. J Neurooncol 2006; 78:31–39.CrossRefPubMedGoogle Scholar
  31. 31.
    Löhr M, Müller P, Karle P et al. Targeted chemotherapy by intratumour injection of encapsulated cells engineered to produce CYP2B1, an ifosfamide activating cytochrome P450. Gene Ther 1998; 5:1070–1078.CrossRefPubMedGoogle Scholar
  32. 32.
    Salmons B, Hauser O, Gunzburg WH et al. GMP production of an encapsulated cell therapy product: issues and considerations. BioProcessing Journal 2007; 4:36–43.Google Scholar
  33. 33.
    Karle P, Müller P, Renz R et al. Intratumour injection of encapsulated cells producing an ifosfamide activating cytochrome P450 for targeted chemotherapy. Adv Exp Med Biol 1998; 451:97–106.PubMedGoogle Scholar
  34. 34.
    Sakai S, Kawabata K, Tanaka S et al. Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy towards chemotherapeutic targeting to tumors. Mol Cancer Ther 2005; 4:1786–1790.CrossRefPubMedGoogle Scholar
  35. 35.
    Ryschich E, Jesnowski R, Ringel J et al. Combined therapy of experimental pancreatic cancer with CYP2B1 producing cells: low-dose ifosfamide and local tumor irradiation. Int J Cancer 2005: 113:649–653.CrossRefPubMedGoogle Scholar
  36. 36.
    Samel S, Lohr M. Targeted intraabdominal chemotherapy for peritoneal carcinomatosis. Cancer Treat Res 2007; 134:469–482.PubMedGoogle Scholar
  37. 37.
    Roy P, Waxman DJ. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol In Vitro 2006; 20:176–186.CrossRefPubMedGoogle Scholar
  38. 38.
    Kammertöns T, Gelbmann W, Karle P et al. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine. Cancer Gene Ther 2000; 7:629–636.CrossRefGoogle Scholar
  39. 39.
    Winiarczyk S, Gradski Z, Kosztolich B et al. Treatment of dogs with mammary tumours using encapsulated, cytochrome P450 synthesising cells thereby activating cyclophosphamide. J Mol Med 2002; 80:610–614.CrossRefPubMedGoogle Scholar
  40. 40.
    Löhr M, Hoffmeyer A, Kröger J et al. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Lancet 2001; 357:1591–1592.CrossRefPubMedGoogle Scholar
  41. 41.
    Löhr JM, Kröger JC, Hoffmeyer A et al. Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I/II trial. Cancer Ther 2003; 1:121–131.Google Scholar
  42. 42.
    Kröger JC, Bergmeister H, Hoffmeyer A et al. Intra-arterial instillation of microencapsulated cells in the pancreatic arteries in pig. Annu NY Acad Sci 1999; 880:374–378.CrossRefGoogle Scholar
  43. 43.
    Kröger JC, Benz S, Hoffmeyer A et al. Intra-arterial Instillation of microencapsulated, ifosfamide activating cells in the pig pancreas for chemotherapeutic targeting. Pancreatology 2003; 3:55–63.CrossRefPubMedGoogle Scholar
  44. 44.
    Günzburg WH, Salmons B. Cell and gene therapy to improve cancer treatment. Acta Biochimica Polonica 2005; 52:601–607.PubMedGoogle Scholar
  45. 45.
    Mellinghoff IK, Sawyers CL. The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics 2002; 3:603–623.CrossRefPubMedGoogle Scholar
  46. 46.
    Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 2005; 4:363–374.PubMedGoogle Scholar
  47. 47.
    Cirone P, Bourgeois JM, Shen F et al. Combined immunotherapy and antiangiogenic therapy of cancer with microencapsulated cells. Hum Gene Ther 2004; 15:945–959.CrossRefPubMedGoogle Scholar
  48. 48.
    Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10:4239–4242.PubMedGoogle Scholar
  49. 49.
    Saller RM, Indraccolo S, Coppola V et al. Encapsulated cells producing retroviral vectors for in vivo gene transfer. J Gene Med 2002; 4:150–160.CrossRefPubMedGoogle Scholar
  50. 50.
    Dvir-Ginzerg, Konson A, Cohen S et al. Entrapment of retroviral vector producer cells in three-dimensional alginate scaffolds for potential use in cancer gene therapy. J Biomed Mater Res B Appl Biomater 2007; 80:59–66.Google Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2010

Authors and Affiliations

  • Brian Salmons
    • 1
  • Walter H. Gunzburg
    • 2
  1. 1.Austrianova Singapore Pte Ltd.Centros SingaporeSingapore
  2. 2.Institute of VirologyUniversity of Veterinary MedicineViennaAustria

Personalised recommendations